Dendritic Cells Transfected with a DNA Construct Encoding Tumour-associated Antigen Epitopes Induce a Cytotoxic Immune Response Against Autologous Tumour Cells in a Culture of Mononuclear Cells from Colorectal Cancer Patients

Scandinavian Journal of Immunology

Volumn 82, Issue 2, 2015, Pages 110-117

  Kulikova, E V ^a   Kurilin, V V ^a   Shevchenko, J A ^a   Obleukhova, I A ^a   Khrapov, E A ^b   Boyarskikh, U A ^b   Filipenko, M L ^b   Shorokhov, R V ^c   Yakushenko, V K ^d   Sokolov, A V ^c   Sennikov, S V ^a  

^a INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

^b INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^c Children Clinical Hospital No 1   (Russian Federation)

^d Regional Veterans Clinical Hospital No 2   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; EPITOPE; MUCIN 4; PERFORIN; TUMOR ANTIGEN; CANCER VACCINE; CELL ADHESION MOLECULE; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL DEATH; CELL LYSATE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DNA TRANSFECTION; FEASIBILITY STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL CULTURE; COLORECTAL TUMOR; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; EPITOPES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MUCIN-4; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84936115138     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12311     Document Type: Article

References (44)

1. Bei R, Scardino A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J Biomed Biotechnol 2010;2010:102758.
2. Scardino A, Alimandi M, Correale P et al. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res 2007;67:7028-36.
3. Nakamura M, Iwahashi M, Nakamori M et al. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Oncology 2005;68:163-70.
4. Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 2011;19:841-53.
5. DeNardo DG, Barreto JB, Andreu P et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91-102.
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
7. Gao WT, Zhang JJ, Zhu Y et al. Pentamer guided HLA-restricted epitope identification for mucoprotein 4 antigen of pancreatic ductal adenocarcinoma. Zhonghua Wai Ke Za Zhi 2010;48:1416-24.
8. Mosolits S, Markovic K, Frödin JE et al. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 2004;10:5391-402.
9. Parkhurst MR, Joo J, Riley JP et al. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 2009;15:169-80.
10. Huang Y, Fayad R, Smock A, Ullrich AM, Qiao L. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res 2005;65:6990-9.
11. Liu KJ, Wang CC, Chen LT et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004;10:2645-51.
12. Bos R, van Duikeren S, van Hall T et al. Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol 2007;179:6115-22.
13. Pietersz GA. Enhanced immune responses to an adenovirus CEA vaccine in CD4+CD25+ regulatory T-cell inactivated mice. Expert Rev Vaccines 2007;6:21-3.
14. Gückel B, Rentzsch C, Nastke MD et al. Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers. J Cancer Res Clin Oncol 2006;132:265-74.
15. Huebener N, Fest S, Strandsby A et al. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol Cancer Ther 2008;7:2241-51.
16. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997;71:8497-503.
17. Boyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest 1968;21:97.
18. Rufer N, Brümmendorf TH, Kolvraa S et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999;190:157-67.
19. Holzhutter HG, Frommel C, Kloetzel PM. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20S proteasome. J Mol Biol 1999;286:1251-65.
20. Tsimokha AS. Proteasomes: their role in cellular processes. Tsitologiia 2010;52:277-300.
21. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
22. Bonehill A, Heirman C, Tuyaerts S et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004;172:6649-57.
23. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004;104:2235-46.
24. Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA. Perforin: structure, function, and role in human immunopathology. Immunol Rev 2010;235:35-54.
25. Zhou F. Perforin: more than just a pore-forming protein. Int Rev Immunol 2010;29:56-76.
26. Burgdorf SK, Fischer A, Myschetzky PS et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep 2008;20:1305-11.
27. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
28. Inzkirweli N, Gückel B, Sohn C, Wallwiener D, Bastert G, Lindner M. Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res 2007;27:2121-9.
29. Lukashina MI, Smirnova AV, Aliyev VA et al. Dendritic cell based vaccines in colorectal cancer therapy. J N N Blokhin RCRC RAMS 2008;19:35-42.
30. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest 2003;21:873-86.
31. Hearn A, York IA, Rock KL. The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J Immunol 2009;183:5526-36.
32. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
33. Tsang KY, Palena C, Yokokawa J et al. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res 2005;11:1597-607.
34. Ojima T, Iwahashi M, Nakamura M et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 2007;120:585-93.
35. Wei J, Gao W, Wu J et al. Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Cancer Biother Radiopharm 2008;23:121-8.
36. Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol 2012;8:1273-99.
37. Merika E, Saif MW, Katz A et al. Review. Colon cancer vaccines: an update. In Vivo 2010;24:607-28.
38. Pernot S, Terme M, Voron T et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 2014;20:3738-50.
39. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98.
40. Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol 2006;176:3374-82.
41. Poehlein CH, Hu HM, Yamada J et al. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol 2003;170:2004-13.
42. Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol 2010;37:1361-78.
43. Schnurr M, Galambos P, Scholz C et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001;61:6445-50.
44. Dong B, Dai G, Xu L et al. Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes. Mol Med Rep 2014;10:2827-34.